# Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET

> **NCT05722925** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **OHSU Knight Cancer Institute** · enrollment: 50 (estimated)

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** Fluciclovine PET/CT

## Key facts

- **NCT ID:** NCT05722925
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-10-04
- **Primary completion:** 2026-12-01
- **Final completion:** 2026-12-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2025-11-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05722925

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05722925, "Evaluating Fluciclovine PET in Patients With Biochemical Recurrence of Prostate Cancer and a Negative PSMA PET". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05722925. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*